InnoStar’s GLP-certified Ophthalmology Integrated Evaluation Platform offers end-to-end, globally compliant "efficacy-PK-toxicity" assessments for diverse ophthalmic drugs, supporting multiple disease models, routes & species to accelerate R&D.

InnoStar offers globally compliant, full-life-cycle DMPK services via its advanced non-clinical PK platform, supporting diverse drug modalities with in vitro/in vivo studies, radioactive ADME work, and aiding over 200 first-in-class projects.

Grand Pharma’s self-developed global innovative RDC drug GPN01530 gets FDA clinical clearance for solid tumor diagnosis, with InnoStar supporting via non-clinical studies.

BoomRay's globally first targeted covalent radiopharmaceutical wins China's clinical trial approval, with InnoStar supporting its progress via non-clinical studies.

InnoStar's professional team ensured the reliability and integrity of the experimental data through a scientifically rigorous approach and highly efficient, precise technical operations. This provided critical data support for the successful clinical approval of Lutetium [177Lu]-BL-ARC001 Injection, accelerating the project's progress.

InnoStar Shanghai will be participating as a key partner at the 23rd SABPA BioPharma Conference, taking place on October 4, 2025, in San Diego, California.